Systemic Juvenile Idiopathic Arthritis Global Market Report 2025

The systemic juvenile idiopathic arthritis market size has grown strongly in recent years. It will grow from $1.28 billion in 2024 to $1.36 billion in 2025 at a compound annual growth rate (CAGR) of 6.1%. Growth during the historic period can be attributed to increasing awareness of early symptoms, rising adoption of biologic therapies, greater emphasis on early diagnosis, increasing healthcare expenditure, expanding government initiatives for pediatric care, and wider availability of advanced diagnostic tools.

The systemic juvenile idiopathic arthritis market size is expected to see strong growth in the next few years. It will grow to $1.7 billion in 2029 at a compound annual growth rate (CAGR) of 5.7%. Growth in the forecast period can be attributed to the increasing adoption of personalized treatment approaches, rising awareness among caregivers and healthcare providers, greater availability of advanced biologic therapies, increasing investments in pediatric healthcare infrastructure, and a stronger focus on early and accurate diagnosis. Major trends expected in the forecast period include the development of targeted biologic therapies, integration of real-world data, innovations in cytokine-targeted treatments, advancements in patient engagement tools, and the creation of combination treatment protocols.

The rising prevalence of autoimmune disorders is expected to drive growth in the systemic juvenile idiopathic arthritis (sJIA) market. Autoimmune disorders occur when the immune system mistakenly attacks healthy tissues, and their increasing prevalence is linked to genetic susceptibility and immune system dysregulation. Systemic juvenile idiopathic arthritis, a distinct autoimmune condition, provides insights into the inflammatory pathways and immune mechanisms underlying widespread tissue damage in autoimmune diseases. For example, according to Arthritis Australia, an estimated 212,136 males and 362,137 females were projected to have rheumatoid arthritis in 2024, with numbers expected to rise by 2040 to approximately 280,040 males and 479,828 females. The growing prevalence of autoimmune disorders like sJIA is therefore driving demand for effective therapies.

Companies in the systemic juvenile idiopathic arthritis market are focusing on innovative therapies, including intravenous (IV) formulations, to enhance treatment efficacy, safety, and patient convenience. IV formulations allow rapid and controlled delivery of drugs directly into the bloodstream, supporting faster therapeutic effects. In October 2025, Celltrion Inc., a South Korea-based biopharmaceutical company, launched AVTOZMA, a tocilizumab biosimilar IV formulation, in the United States. AVTOZMA offers treatment for sJIA, rheumatoid arthritis, and cytokine release syndrome, providing a cost-effective alternative to the reference product Actemra. By offering both IV and subcutaneous options, AVTOZMA improves patient access, enhances flexibility for clinicians, and supports personalized treatment regimens.

In April 2025, Organon & Co., a US pharmaceutical company, acquired Tofidence (tocilizumab-bavi), a biosimilar to Actemra, from Biogen. This acquisition expanded Organon’s U.S. immunology and arthritis portfolio, enabling broader access to multi-indication arthritis therapies and reinforcing the development of effective treatments for systemic juvenile idiopathic arthritis.

Major companies operating in the systemic juvenile idiopathic arthritis market are Johnson And Johnson, F. Hoffmann-La Roche Limited, Merck & Co. Inc., Pfizer Inc., AbbVie Inc., Sanofi S.A., Novartis AG, AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly And Company, Takeda Pharmaceutical Company Limited, Amgen Incorporated, Boehringer Ingelheim, Regeneron Pharmaceuticals Incorporated, Chugai Pharmaceutical Company Limited, Genentech Incorporated, Swedish Orphan Biovitrum Aktiebolag, Zydus Lifesciences Limited, Celltrion Incorporated, Mycenax Biotech Incorporated.

North America was the largest region in the systemic juvenile idiopathic arthritis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in systemic juvenile idiopathic arthritis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the systemic juvenile idiopathic arthritis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

The systemic juvenile idiopathic arthritis market research report is one of a series of new reports that provides systemic juvenile idiopathic arthritis market statistics, including systemic juvenile idiopathic arthritis industry global market size, regional shares, competitors with a systemic juvenile idiopathic arthritis market share, detailed systemic juvenile idiopathic arthritis market segments, market trends and opportunities, and any further data you may need to thrive in the systemic juvenile idiopathic arthritis industry. This systemic juvenile idiopathic arthritis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Systemic juvenile idiopathic arthritis (SJIA) is a rare form of childhood arthritis that causes widespread inflammation throughout the body, not just in the joints. It is marked by recurring high fevers, a distinctive rash, and swelling or pain in multiple joints. Unlike other juvenile arthritis types, SJIA can also affect internal organs such as the liver, spleen, and heart. The exact cause remains unknown but is thought to be linked to an abnormal immune response.

The main treatment types for systemic juvenile idiopathic arthritis include drug treatment, biologics, and other therapeutic options. Drug treatment refers to the use of medications - such as biologics, corticosteroids, and disease-modifying antirheumatic drugs (DMARDs) - to reduce inflammation, manage symptoms, and prevent joint damage in patients with SJIA. Treatment is provided across various age groups, including infants, children, and adolescents. These therapies are distributed through hospital pharmacies, retail pharmacies, and online pharmacies and are utilized by multiple end users, including hospitals, specialty clinics, academic research centers, and others.

The systemic juvenile idiopathic arthritis market consists of revenues earned by entities by providing services such as pharmaceutical treatments, clinical consultation services, hospital and outpatient care, diagnostic services, and supportive care services. The market value includes the value of related goods sold by the service provider or included within the service offering. The systemic juvenile idiopathic arthritis market also includes sales of canakinumab, tocilizumab, methotrexate, corticosteroids, and nonsteroidal anti-inflammatory drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.